ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Although c-Abl-specific tyrosine kinase inhibitors (TKIs) substantially extend the survival of patients with chronic myeloid leukemia (CML), TKIs fail to eliminate leukemic stem cells resulting in minimal residual disease.